查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198340

一次性組裝市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Single-Use Assemblies Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，一次性組裝市場預計將以 19.5% 的複合年增長率增長。

由於在 COVID-19 疫苗開發的研究活動中越來越多地採用一次性技術，COVID-19 對一次性組裝市場產生了重大影響。 許多參與者將研發工作集中在需要一次性組裝的疫苗開發上。 在大流行期間，供應商努力跟上需求，推動一次性組件的市場增長。 例如，根據 2021 年 5 月發表在 Bioprocess International 上的一篇文章，在 COVID-19 大流行期間，一次性生物工藝系統和材料已被確定為潛在疫苗和治療開發以及工業製造的關鍵資源。需求量很大。 由於所需的速度和靈活性，用於製造創新疫苗（例如 mRNA、DNA 和病毒載體）的平台通常使用一次性技術構建。 對一次性組件的高需求可能對大流行期間的市場增長產生了積極影響。 此外，即使在大流行之後，由於生物製藥和製藥公司在開發和製造治療 COVID-19 和其他疾病的藥物期間越來越多地採用一次性組件，需求仍然強勁，這推動了市場的增長。 因此，預計未來三到四年將保持穩定增長。

市場增長因素包括快速簡便的部署、低交叉污染風險、生物製藥公司增加研發投資以及生物製劑市場的增長。 由於降低交叉污染風險、簡化清潔程序和定制解決方案等好處，全球生物製藥行業隨著時間的推移越來越多地採用一次性組件。 這加速了藥物開發和製造過程。

生物製藥公司不斷增加的研發投資也促進了一次性組裝市場的增長。 發達國家的研發支出和新藥引進顯著增加。 例如，根據 EFPIA 的數據，歐洲製藥公司在 2021 年的研發支出估計為 415 億歐元。 因此，隨著在研究中的開發、測試和擴展中越來越多地採用一次性組件，預計如此大量的研發支出將推動市場增長。

此外，市場參與者不斷增加的舉措（例如合作夥伴關係和收購）預計也將推動市場增長。 例如，2021 年 6 月，Avantar 收購了 RIM Bio，這是一家中國生物製藥製造一次性生物工藝袋和組件製造商。 此次收購將使 Avantar 能夠使用 RIM 在中國常州的工廠，使其成為 Avantar 在非洲、中東和亞洲 (AMEA) 地區的首批一次性生產單位之一。 Avantor 將利用 RIM 的專有技術和較短的交貨時間，使其面向一次性客戶的服務與眾不同。 此類案例將推動各個地區採用一次性組件並促進市場增長。

因此，一次性組裝相對於傳統工藝的優勢以及生物製藥領域不斷增加的研發活動正在推動市場增長。 然而，與可提取物和可浸出物相關的問題預計會阻礙市場增長。

一次性組件的市場趨勢

生物製藥和醫藥企業佔比較大

生物製藥和製藥公司廣泛使用一次性組件和耗材，例如無菌瓶轉移裝置、一次性歧管和定制管道套件，以簡化上游流程。 生物製藥和製藥公司在研發上的支出顯著增加。

生物製藥製造中越來越多地採用一次性組件，預計將進一步推動該領域的增長。 Wiley Online Library 上發表的一項研究表明，一次性組件的使用已成為生物製藥加工研究、放大和商業生物製造中必不可少的。 因此，一次性組裝在生物製藥和藥物研究中的重要性預計將因其越來越多的採用而推動該領域的增長。

此外，主要市場參與者為擴展服務而採取的更多舉措預計將推動市場增長。 例如，2022 年 9 月，默克在法國莫爾塞姆投資超過 1.3 億歐元，以加強其用於製造 COVID-19 疫苗和其他救生治療的一次性組件的製造能力。 隨著一次性組件越來越多地被發達國家的製藥和生物製藥公司採用，這些努力有望推動該領域的增長。

此外，預計每個國家/地區人均醫療保健支出的增加將增加獲得創新藥物的機會。 因此，由於需求的增加，公司在藥物研發上投入了大量資金。 因此，製藥和生物製藥公司越來越需要一次性組件。

因此，在生物製藥研究中越來越多地採用一次性組件以及主要市場參與者不斷增加的投資等因素預計將在預測期內推動生物製藥和製藥公司部門的快速增長。

北美是重要市場

北美的市場份額主要受成熟的生物製藥行業、區域市場領導者廣泛使用一次性組件以及生物製劑和生物仿製藥製造的增加推動。

美國有利的國內環境和先進的生物製藥和製藥行業貢獻了一次性組裝市場的很大份額。

2021 年 7 月，Cytiva 和 Pall Corporation 投資 15 億美元，以滿足對生物技術解決方案不斷增長的需求。 此次擴建將提供製造生物製藥的基本產品，包括用於培養細胞的生物反應器袋等一次性技術，用於製造個性化藥物和用於科學研究的注射器過濾器。產量將增加。 由於越來越多地採用一次性組件來製造生物製品，預計此類投資將進一步推動北美研究市場的增長。

此外，根據加拿大健康信息研究所 2022 年的數據，加拿大的醫療保健總支出正在增加，到 2021 年將達到 3080.43 億美元。 如此高的加拿大醫療保健支出將增加創新藥物的支出，導致藥物和生物製藥研究的增加，從而增加一次性組件的採用，從而增加研究市場的規模。預計將推動增長。

因此，研發支出增加和醫療保健進步等因素可能會推動北美市場的增長。

一次性組裝市場競爭對手分析

一次性組裝市場競爭適中，由許多重要參與者組成。 從市場份額的角度來看，一些主要參與者主導著市場。 市場受到諸如一次性組件發布增加、研發採用率增加和製藥製造等因素的推動。 市場上的公司包括 Sartorius AG、Thermo Fisher Scientific、Danaher Corporation、Merck KGaA、Avantor Inc.、Parker Hannifin Corporation 和 Saint-Gobain。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 調查先決條件和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 快速部署和低交叉污染風險
    • 生物製藥公司的研發投資增加
    • 不斷增長的生物製品市場
  • 市場製約因素
    • 與可提取物和可浸出物相關的問題
  • 行業吸引力 - 波特五力分析
    • 新進入者的威脅
    • 買家的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按產品類型
    • 過濾組件
    • 包組裝
    • 瓶子組裝
    • 混合系統組件
  • 通過申請
    • 細胞培養/混合
    • 過濾
    • 存儲
    • 抽樣
    • 填充和精加工應用
    • 其他應用（無菌運輸和流體管理）
  • 最終用戶
    • 生物製藥和製藥公司
    • 承包研究/承包製造組織
    • 學術和研究機構
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Thermo Fisher Scientific
    • Sartorius AG
    • Danaher（Pall Corporation）
    • Merck KGaA
    • Avantor
    • Lonza
    • Parker Hannifin Corporation
    • Saint-Gobain
    • Repligen Corporation
    • Corning Incorporated
    • Entegris
    • Antylia Scientific（Cole-Parmer）

第7章 市場機會與今後動向

簡介目錄
Product Code: 72389

The single-use assemblies market is projected to register a CAGR of 19.5% during the forecast period.

There was a significant impact of COVID-19 on the single-use assemblies market as there was growing adoption of single-use technology for research activities in COVID-19 vaccine development. Many players focused on R&D activities to develop a vaccine requiring single-use assemblies. The suppliers struggled to keep up with demand during the pandemic, propelling the market growth of single-use assemblies. For instance, according to the article published in Bioprocess International in May 2021, single-use bioprocess systems and materials were in high demand during the COVID-19 pandemic as essential resources for the development and industrial manufacture of potential vaccines and treatments. The platforms used to create innovative vaccines, such as mRNA, DNA, and viral vectors, were generally constructed using single-use technologies due to the speed and flexibility required. The high demand for single-use assemblies might have positively impacted the market growth during the pandemic. Furthermore, post-pandemic, the demand was still persistent due to the increased adoption of single-use assemblies during the development and manufacture of COVID-19 and other diseases therapies by the biopharmaceutical and pharmaceutical companies driving the market growth. Thus, the market is expected to witness stable growth over the next 3-4 years.

Factors driving the market growth include rapid and easy implementation, a low risk of cross-contamination, increased R&D investment by biopharmaceutical companies, and a growing biologics market. The adoption of single-use assemblies in the global biopharmaceutical community has increased over time due to its advantages, such as the decreased chances of cross-contamination hazards, simplified cleaning procedures, and customized solutions by using single-use assemblies. This helps accelerate drug development and the manufacturing process.

Increased R&D investment by biopharmaceutical companies is also contributing to the growth of the single-use assembly market. There is a vast increase in R&D spending and the introduction of new drugs in developed nations. For instance, according to the EFPIA, the estimated R&D expenditure of European pharmaceutical companies in 2021 was EUR 41,500 million. Therefore, such a considerable R&D expenditure is expected to drive market growth due to the increased adoption of single-use assemblies in development, testing, and scaling in research, driving the market growth.

Furthermore, rising initiatives from the market players, such as partnerships and acquisitions, are also expected to propel the market growth. For instance, in June 2021, Avantor acquired RIM Bio, a Chinese maker of single-use bioprocess bags and assemblies for biopharmaceutical production. By this acquisition, Avantor will access RIM's Changzhou, China, facility, making it Avantor's one of the first single-use production units in Africa, the Middle East, and Asia (AMEA) region. Avantor intends to differentiate its services for single-use clients by leveraging RIM's exclusive technology and short lead times. Such instances lead to increased adoption of single-use assemblies across different geographies, bolstering the market growth.

Therefore, the advantages of single-use assemblies over traditional processes and increased biopharmaceutical R&D activities propel market growth. However, issues related to extractables and leachables are expected to hamper the market growth.

Single-Use Assemblies Market Trends

Biopharmaceutical & Pharmaceutical Companies Segment Accounted Significant Market Share

Biopharmaceutical and pharmaceutical companies extensively use single-use assemblies and consumables, including aseptic bottle transfers, single-use manifolds, and custom tube kits, to streamline the upstream process. The amount of money spent on research and development by biopharmaceutical and pharmaceutical firms has increased to a large extent.

The rising adoption of single-use assemblies in biopharmaceutical manufacturing is expected to further drive this segment's growth. A study published in Wiley Online Library shows that using single-use assemblies has become essential in biopharma processing research, scale-up, and commercial biomanufacturing. Therefore, the importance of single-use assemblies in biopharmaceutical and pharmaceutical research is expected to drive segment growth due to increased adoption.

In addition, the key market players' rising initiatives by expanding their services are expected to drive market growth. For instance, in September 2022, Merck strengthened its manufacturing capabilities for single-use assemblies to produce COVID-19 vaccines and other lifesaving therapies by investing more than EUR 130 million in Molsheim, France. Such initiatives are expected to drive segment growth due to the increased adoption of single-use assemblies by pharmaceutical and biopharmaceutical companies in developed nations.

Additionally, the increasing per capita healthcare expenditure in the countries is expected to increase the accessibility of innovative drugs. Hence, companies are spending more on the research and development of drugs due to their increasing demand. Thus there is a rising need for single-use assemblies in pharmaceutical and biopharmaceutical companies.

Therefore, factors such as the rising adoption of single-use assemblies in biopharmaceutical research and rising investments from the key market players are expected to drive the growth of the biopharmaceutical and pharmaceutical companies segment at a significant pace over the forecast period.

North America Holds a Significant Market

The factors accounting for the significant share of the market include the well-established biopharmaceutical sector, widespread availability of single-use assemblies supplied by regional market leaders, and rising biologics and biosimilar manufacturing.

The supportive domestic environment and sophisticated biopharmaceutical and pharmaceutical sectors in the United States contribute a significant share of the single-use assembly market.

In July 2021, Cytiva and Pall Corporation invested USD 1.5 billion to meet the growing demand for biotechnology solutions. This expansion will increase the manufacture of essential products used to make biological medicines, such as single-use technologies, including bioreactor bags for growing cells used to create personalized medication and syringe filters for scientific research. Such investments are further expected to drive the growth of the market studied in North America due to the rise in the adoption of single-use assemblies to manufacture biologics.

Furthermore, according to the Canadian Institute for Health Information 2022, the total healthcare expenditure was increasing in Canada and was USD 3,08,043 million in 2021. Such a significant expenditure on healthcare in Canada is expected to drive the growth of the market studied as there would be increasing spending on innovative drugs, leading to increasing pharmaceutical and biopharmaceutical research, thereby raising the adoption of single-use assemblies.

Therefore, factors such as rising R&D expenditure and advancements in healthcare, among others, are expected to drive market growth in North America.

Single-Use Assemblies Market Competitor Analysis

The single-use assembly market is moderately competitive and consists of many significant players. In terms of market share, a few major players dominate the market. The market is driven by factors such as the rising launch of single-use assemblies, increased research and development adoption, and pharmaceutical manufacturing. Some companies operating in the market are Sartorius AG, Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Avantor Inc., Parker Hannifin Corporation, and Saint-Gobain.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope Of The Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapid Implementation and Low Risk of Cross-contamination
    • 4.2.2 Increasing R&D Investment by Biopharmaceutical Companies
    • 4.2.3 Growing Biologics Market
  • 4.3 Market Restraints
    • 4.3.1 Issues Related to Extractables & Leachables
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Filtration Assemblies
    • 5.1.2 Bag Assemblies
    • 5.1.3 Bottle Assemblies
    • 5.1.4 Mixing System Assemblies
  • 5.2 By Application
    • 5.2.1 Cell Culture and Mixing
    • 5.2.2 Filtration
    • 5.2.3 Storage
    • 5.2.4 Sampling
    • 5.2.5 Fill-finish Application
    • 5.2.6 Other Applications (Aseptic Transfer and Fluid Management)
  • 5.3 By End-user
    • 5.3.1 Biopharmaceutical and Pharmaceutical Companies
    • 5.3.2 Contract Research and Contract Manufacturing Organizations
    • 5.3.3 Academic and Research Institutes
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific
    • 6.1.2 Sartorius AG
    • 6.1.3 Danaher (Pall Corporation)
    • 6.1.4 Merck KGaA
    • 6.1.5 Avantor
    • 6.1.6 Lonza
    • 6.1.7 Parker Hannifin Corporation
    • 6.1.8 Saint-Gobain
    • 6.1.9 Repligen Corporation
    • 6.1.10 Corning Incorporated
    • 6.1.11 Entegris
    • 6.1.12 Antylia Scientific (Cole-Parmer)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS